Skip to search formSkip to main contentSkip to account menu

100 ML Immunoglobulin G, Human 100 MG/ML Injection [Privigen]

Known as: Privigen 10 GM per 100 ML Injection, privigen 10 % in 100 ML Injection, Human Immunoglobulin G 10 g in 100 mL INTRAVENOUS LIQUID [Privigen] 
National Institutes of Health

Related topics

Related topics

6 relations
Albumin Human, USPImmunoglobulin A, HumanImmunoglobulin G, HumanInjection

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency
Abstract This prospective, Phase 3, open-label, study (EudraCT: 2016-001631-12) evaluated pharmacokinetic (PK) characteristics of… 
2019
2019
Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency
2017
2017
Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
Author(s): Suez, Daniel; Stein, Mark; Gupta, Sudhir; Hussain, Iftikhar; Melamed, Isaac; Paris, Kenneth; Darter, Amy; Bourgeois… 
2016
2016
Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment
Hemolysis, a rare but potentially serious complication of intravenous immunoglobulin (IVIG) therapy, is associated with the… 
2014
2014
A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
Highly Cited
2013
Highly Cited
2013
Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)
This prospective, multicenter, single‐arm, open‐label Phase III study aimed to evaluate the efficacy and safety of Privigen® (10… 
Highly Cited
2012
Highly Cited
2012
Treatment of multiple system atrophy using intravenous immunoglobulin
BackgroundMultiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as… 
2011
2011
L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use.
Liquid IgG preparations are preferred over lyophilized preparations because reconstitution is not required. Formation of dimers… 
2010
2010
Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates
PurposeThe tolerability of L-proline-stabilized Privigen®, a new 10% liquid immunoglobulin for intravenous administration, was… 
2009
2009
Efficacy and safety of privigen in children and adolescents with primary immunodeficiency.
The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)